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Abstract 
Background: Recent studies indicated that histone deacetylase inhibitors (HDACi), a class of anticancer agents, are 
in addition to their ability of apoptosis induction also capable of provoking autophagy. Promoted by the treatment of 
malignant uterine sarcoma cells with the HDACi suberoylanilide hydroxamic acid (SAHA), we previously demonstrated 
predominant dose-dependent activation of autophagy in ESS-1 cells, but prevalent induction of apoptosis in MES-SA 
cells.
Methods: In order to extend our previous studies, SAHA-treated ESS-1 and MES-SA cells were monitored for protein 
expression to reveal differences in known markers of apoptosis explaining the different cytotoxic responses. Further 
analysis of the identified candidate protein included cell rescue experiments by gene transfer followed by subsequent 
screening of cells for induction of apoptosis and autophagy by immunoblotting, caspase activity as well as LC3 and 
MDC/PI staining. LDH release assays were performed to assess the amount of cell-mediated cytotoxicity.
Results: In our search for responsible autophagic regulatory genes upstream of mammalian target of rapamycin 
(mTOR), we now discovered that, in contrast to MES-SA cells, a TP53-637C>T nonsense mutation located in the trans-
activating domain of the oncogenic suppressor p53 causes loss of its protein and consequently reduced PUMA induc-
tion in ESS-1 cells. Upon re-introduction of wild-type TP53, SAHA-treated ESS-1 cells underwent immediate apoptotic 
cell death as supported by upregulation of PUMA and caspase-9 as well as by activation of caspases-3 and -7 and 
PARP-1 cleavage. Concurrent downregulation of autophagy was noticed by upregulated mTor and phospho-mTOR 
expression as well as monitoring autophagosome formation employing LC3 and MDC staining. Previously, cytoplas-
mic master regulatory activities of the oncogenic suppressor p53 in inhibiting autophagy and triggering apoptosis 
were unravelled. Accordingly, p53-deficiency could explain both, the previously documented apoptosis resistance 
and prevailing SAHA-induced autophagy in ESS-1 cells. Using MES-SA cells with RNAi-silenced p53 expression and 
several p53-deficient tumor cell lines undergoing SAHA-induced autophagy, we could generally validate our finding 
suggesting an inhibitory role for p53 in the autophagic pathway in response to SAHA treatment.
Conclusions: Conclusively, these results could identify cytoplasmic p53 protein as a molecular switch that directly 
mediates the cytotoxic response of SAHA and thus open new therapeutic avenues.
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Background
HDACi are a well-characterized class of cancer therapeu-
tic agents with promising clinical activity against hemato-
logic and solid tumors at well tolerated doses by patients 
[1, 2]. HDAC expression is essential in the establishment 
of a transcriptionally inactive chromatin structure by 
posttranslationally modifying histone and nonhistone 
acetylation sites [3]. Counteracting the effects of HDACs 
by inhibition of HDAC activity therefore induces chro-
matin relaxation which leads to altered expression of 
only few but important genes involved in the regulation 
of many disbalanced tumor cell processes as cell cycle 
arrest, differentiation, and apoptosis. In various tumor 
cell lines, treatment with HDACi most frequently induces 
apoptosis by sequential activation of a series of cysteine-
dependent aspartate-directed proteases, called caspases 
[4, 5]. Nevertheless, their precise mode of function in 
selectively eliminating malignant cells remains unclear.
Suberoylanilide hydroxamic acid (SAHA), an inhibi-
tor of class I and II HDACs, was previously admitted for 
therapeutic treatment of cutaneous T cell lymphoma 
[6]. As a single molecule, SAHA has broad range effects 
which include the inhibition of cell proliferation by 
blocking cell cycle progression, the suppression of angio-
genesis, the induction of cellular differentiation, as well as 
apoptosis in tumor cells [7, 8]. Among other studies, we 
previously demonstrated that SAHA can, in addition to 
mitochondria-mediated apoptosis, also promote caspase-
independent autophagic cell death [9–11] which offers 
an advantage in overcoming apoptotic resistant tumor 
cells. This coincided with decreased expression of the 
autophagic key molecular determinant mTOR, a master 
regulator of cellular metabolism which is a therapeutic 
target for anticancer treatment. Furthermore, phospho-
S6 ribosomal protein (S6rp) which controls cell cycle 
progression was found to be downregulated. The studies 
of Gammoh et  al. supported SAHA-mediated suppres-
sion of mTOR during activation of autophagy and further 
elaborated its downstream pathway [12]. It was found 
that the nutrient-sensing kinase prevents the formation of 
autophagy by phosphorylation and thereby inactivation 
of the ULK1 complex; the important role of this further 
central component in autophagy was previously demon-
strated by ULK1-deficient cells. mTOR inactivation by 
SAHA thus rescues ULK1 activation and thereby induces 
autophagy. ULK1 (and PI3 K) complexes subsequentially 
activate the proper autophagy-related proteins including 
the ATG12-ATG5 and LC3-phosphatidylethanolamine 
complexes that are directly involved in formation of the 
mature autophagosome [13, 14]. The later involves the 
nucleation and elongation of the double-membrane vesi-
cle and its fusion with the lysosome leading to the final 
degradation of the autophagosome content [15]. Upon 
conjugation to ubiquitin-like conjugation systems, cyto-
solic LC3 (termed LC3-I) gets incorporated to the grow-
ing autophagosome structure (then termed LC3-II) and 
therefore acts as a marker [16, 17].
Currently, molecular mechanisms by which SAHA 
modulates and thereby initiates autophagic induction 
upstream of mTOR remain unknown. In the absence 
of any observed transcriptional regulation of mTOR or 
upstream pathway components, the possibility remains 
that SAHA suppresses mTOR by interfering with the 
acetylation of regulatory nonhistone proteins. In this 
regard, the transcription of LC3 itself was found to be 
upregulated by SAHA, as well as downregulated by p53 
which seems to support cancer cell survival under star-
vation conditions; nevertheless, LC3 itself is not capable 
of inducing autophagy [12, 18]. Previously, consistently 
detected upregulated expression of the class II enzyme, 
HDAC2, in endometrial stroma sarcoma (ESS) led us 
to study the therapeutic options of the HDACi SAHA 
[19]. Our group verified that SAHA exerts cytotoxic-
ity on uterine sarcoma cells and significantly prevented 
tumor cell proliferation by increasing expression of 
the cell cycle kinase p21WAF1 and decreasing expres-
sion of HDAC2 and 7 in vitro [10]. The number of cells 
was decreased in a time- and dose-dependent manner 
whereby an established working dose of 3 µM SAHA sig-
nificantly reduced ESS-1 cells by 80 % and MES-SA cells 
by 48 % after 24 h of treatment, and inhibited the G1/S 
transition [20]. Moreover, we documented pronounced 
activation of apoptosis in MES-SA uterine sarcoma 
cells in xenografted tumors and in  vitro [21], but pre-
dominant SAHA-mediated dose-dependent autophagic 
cell death in malignant ESS-1 cells accompanied by 
decreased expression of mTOR [10]. During further 
experiments with combined SAHA and tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL) treat-
ment, we noticed a rapidly enhanced cytotoxic effect 
which led to complete cell death after 24 to 48 h. In both 
tumor cell lines, induction of combined SAHA- and 
TRAIL-induced apoptosis was accompanied by upregu-
lation of the intrinsic/mitochondrial apoptotic pathway 
[20]. In the present study, we wanted to further clarify 
the cause for the different mode of cell death in both 
sarcoma cell lines related to single SAHA treatment 




SAHA was purchased from Alexis Biochemicals (Lausen, 
Switzerland). A 10  mM stock solution was prepared 
with dimethyl sulfoxide (DMSO) and stored at −20  °C. 
DMSO never exceeded a concentration of 0006  % in 
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any experiment and therefore did not interfere with cell 
growth. RhTRAIL/APO-2L was purchased from eBio-
sciences (Vienna, Austria; 10  ng/µl) or Biomol (Ham-
burg, Germany; 1  µg/µl). Ampicillin, Hoechst 33258 
solution, monodansylcadaverine (MDC), propidium 
iodide solution (PI) (1.0 mg/ml in water), and rapamycin 
(2.5  mg/ml solution in 2.74  mM DMSO) were received 
from Sigma-Aldrich (Vienna, Austria). Paraformaldehyde 
was acquired from Merck (Darmstadt, Germany). Inhibi-
tors for caspase-3 (Z-DEVD-FMK), -8 (Z-IETD-FMK), 
-9 (Z-LEHD-FMK) and the caspase-family inhibitor 
(Z-VAD-FMK) were obtained from BioVision (Milpitas, 
CA, USA).
Cell culture
The human uterine sarcoma cell line MES-SA [22], 
derived from the sarcomatous element of a mixed mül-
lerian tumor (carcinocarcinoma), was obtained from 
ATCC (ATCC Nr. CRL-1976) and cultured in McCoys 5a 
medium (Biochrom AG; Berlin, Germany). The human 
ESS cell line, ESS-1 [23], was purchased from the German 
Collection of Microorganisms and Cell Cultures (Braun-
schweig, Germany) and cultured in RPMI 1640 medium 
(PAA; Pasching, Austria). HeLa, PANC-1, Jurkat, HL-60, 
and U937 tumor cell lines were obtained from the Cell 
Culture Core Facility of the Medical University of Graz. 
HeLa and PANC-1 cells were cultured in DMEM con-
taining 4.5  g/l glucose (LifeTech; Vienna, Austria). The 
suspension cells Jurkat, HL-60, and U937 were grown in 
RPMI1640 medium (Biochrom AG; Berlin, Germany). All 
cell culture media were additionally supplemented with 
heat-inactivated fetal calf serum (10 %, v/v), 100 units/ml 
penicillin, 100  μg/ml streptomycin, and 2  mM of stable 
glutamine. Cells were cultured under standard conditions 
(37 °C, 5 % CO2, and 95 % humidity). Experiments were 
only conducted with cell passage numbers below 20.
Mutation analysis of TP53 by DNA sequencing
Cells were grown to confluency and after a wash with 
1× PBS, genomic DNA was extracted by incubating 
cells with Proteinase K digestion buffer (50  mM Tris–
HCl pH 8.0, 100 mM EDTA pH 8.0, 100 mM NaCl, 1 % 
SDS, 0.1 mg/ml Proteinase K) at 37 °C over night. TP53 
exons were amplified from the isolated genomic DNA 
according to standardized primer sequences and PCR 
conditions of the IARC TP53 database protocol (http://
p53.iarc.fr/Download/TP53_DirectSequencing_IARC.
pdf). PCR products were inserted into pCR4-TOPO 
vector (LifeTech; Vienna, Austria) and transformed into 
the supplied One Shot TOP10F´ chemically competent 
E. coli cells. Transformed cells were grown on a LB plate 
containing 0.1 mg/ml ampicillin. Subclones were submit-
ted for sequencing by the Sanger method for each exon 
(GATC Biotech AG; Cologne, Germany). The presence 
or absence of the TP53 mutation was confirmed by more 
than tenfold re-sequencing of further ESS-1 subclones 
or the corresponding control region in MES-SA cells, 
respectively.
Caspase activity and LDH assays
Caspase activity in the cell lysates was determined by 
using the Caspase-Glo 3/7 Assay (Promega; Mannheim, 
Germany) as previously described [24]. For individual 
assays, 5  ×  103  cells per well were seeded in 96-well 
plates (Corning Costar; Amsterdam, The Netherlands), 
incubated at 5  % CO2 and 37  °C, and the appropri-
ate treatment was started 24  h later. Release of lactate 
dehydrogenase (LDH) into cell supernatant was meas-
ured using the CytoTox-ONE homogeneous membrane 
integrity assay (Promega GmbH; Mannheim, Germany) 
according to the manufacturer´s instructions and as pre-
viously specified [24]. For a positive control, cells were 
treated with a lysis solution of equal amounts of Triton 
X-100 and 70 % ethanol for 10 min at room temperature 
(RT). Results are expressed as percentage of relative LDH 
release compared to the lysis control. In both assays each 
experiment included interference controls containing no 
cells with the maximal concentration applied for each 
treatment, as well as untreated and medium controls. 
Caspase inhibitors were administered directly to the cells 
1 h prior to the start of the treatment at a concentration 
of 10 µM, if required.
Detection of autophagy/cytotoxicity by MDC/PI staining
For visualization and fluorometric quantification of 
autophagic cells as well as dead cells, respectively, stain-
ing with the autofluorescent drug MDC, a specific 
autophagolysosome marker [25], and PI was achieved 
as described previously [26]. 150 × 103 cells were plated 
out on 6-well borosilicate glass plates (Asahi Glass Co.; 
Tokyo, Japan) and treatment was started 24  h later fol-
lowed by 12  h of incubation at 5  % CO2 and 37  °C. 
Then, cells were washed once in 1× PBS and incubated 
for 5  min at RT with 100  µl of the cell-based PI solu-
tion added to each well and protected from light. After 
washing individual wells with 100  µl of 1× PBS, cells 
were incubated with 0.05 mM MDC in PBS at 37 °C for 
60 min and protected from light. Cells were washed again 
in 1× PBS before they were left in 1× PBS and imme-
diately photographed at a Zeiss confocal laser scanning 
microscope by using the Zeiss 1003 oil immersion lens 
and the LSM510 Meta software (Zeiss; Oberkochen, 
Germany). Images were acquired at an excitation wave-
length of 514  nm for the green channel (MDC) and of 
633  nm for the red channel (PI). In order to quantify 
MDC/PI staining, cells were monitored by fluorescence 
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spectrophotometry (Hitachi F-2500; Tokyo, Japan) at 
excitation and emission wavelengths of 335 and 512 nm 
for MDC, respectively, and at excitation and emission 
wavelengths of 530 and 590  nm for PI, respectively. 
Incorporated MDC and PI were expressed in arbitrary 
units. Cells treated with rapamycin presented the posi-
tive control while untreated cells were included as a neg-
ative control. For normalization of cell numbers among 
different samples, MDC and PI fluorescence was adjusted 
to equal DNA content by Hoechst staining. After adding 
1 ml of Hoechst 33258 solution (1 mg/ml) to each well, 
cells were incubated for 10  min and then measured at 
an excitation/emission wavelength of 365/460  nm. All 
observations were reproduced at least three times in 
independent experiments.
Western blot analysis
Cell lysates and Western blots were prepared as previ-
ously described [20]. Following antibodies and concen-
trations/dilutions were used: rabbit anti-PUMA (1  μg/
ml)/1:1000; rabbit anti-cleaved CASP-9 (1 μg/ml)/1:1000; 
rabbit anti Cleaved poly-ADP-ribose polymerase-1 
(PARP-1)/1∶1000 (Cell Signaling; Frankfurt, Germany); 
purified mouse anti-human p53 (0.5 mg/ml)/1:100 (clone 
DO-7; BD Pharmingen; Schwechat, Austria); mouse anti-
p21WAF1 (0.5 μg/ml)/1:2000 (Zymed; San Francisco, CA, 
USA); polyclonal rabbit anti-human phospho-mTOR 
(Ser2448) and mTOR Antibody (#2972) Antibody (Cell 
signaling; Frankfurt, Germany). As secondary antibod-
ies, we used rabbit anti-mouse and swine anti-rabbit 
HRP-conjugated antibodies at a final concentration 
of 1  μg/ml/1:1000 (DAKO; Copenhagen, Denmark). 
Specific protein bands were visualized by enhanced 
chemiluminescence assay (Amersham Biosciences; Buck-
inghamshire, England). All Western blots were probed 
with a polyclonal rabbit anti β-tubulin antibody (Anti-
TubA8/1:1000) (Sigma-Aldrich, Vienna, Austria) to dem-
onstrate equal protein loading. Protein expression was 
quantified using Image J software.
TP53 gene transfer
The expression vector pCMV6-XL5 containing the 
human full-length cDNA for TP53 (TP53-WT) (NCBI 
Acc.-No: NM_000546.2; SC119832) was obtained from 
OriGene (Rockville, CA, USA). Originating from TP53-
WT, a control vector containing the 637C>T muta-
tion was constructed (TP53-637C>T) by using the 
QuikChange II Site-Directed Mutagenesis Kit (Agilent 
Technologies; CA, USA). Briefly, the mutagenic primer 
hTP53-637C>TFwd 5′-GATGACAGAAACACTTTTT-
GACATAGTGTGGTGGTG-3′ was used to synthe-
size a mutant strand by thermal cycling using PfuUltra 
DNA polymerase followed by DpnI restriction of the 
methylated parental template. Upon transformation of 
One Shot TOP10F′ chemically competent E. coli cells and 
selection, plasmid DNA of ampicillin-resistant colonies 
was isolated and submitted for sequencing in order to 
confirm the correct nucleotide sequence (GATC Biotech 
AG; Cologne, Germany). TP53-WT or TP53-637C>T 
were transiently transfected using Lipofectamine 2000 
transfection reagent (Life Tech; Vienna, Austria) with a 
DNA (μg) to Lipofectamine (μl) ratio of 1:2.5. Co-trans-
fections with the pEGFP-N1 plasmid (Clontech, Gen-
Bank acc. no. U55762; Mountain View, CA, USA) were 
performed to assure a high percentage of transfection 
efficiency (>85 %). The appropriate treatment was started 
24 h after transfection.
RNA interference
MES-SA cells were transiently transfected with 50 or 
100  nM SignalSilence p53 si-RNA I or 100  nM non-
targeted control si-RNA (Cell Signaling) using Lipo-
fectamine 2000 transfection reagent. SAHA treatment 
was started 24  h after transfection and cells were har-
vested 36 h later for Western blot analysis.
LC3 immunostaining
5 × 104 cells per well were seeded in 24-well borosilicate 
glass plates (Asahi Glass Co., Tokyo, Japan) and incu-
bated at 5 % CO2 and 37  °C. After 24 h, transfection of 
cells containing TP53-WT or TP53-637C>T plasmids 
was performed as described above and treatment of non-
transfected control cells was initiated. After further incu-
bation for 12  h, cells were washed once in 1× PBS and 
fixed with 3.7 % paraformaldehyde in PBS for 10 min at 
RT. Then, cells were washed again with 1× PBS and per-
meabilized with ice-cold methanol for 10 min at −20 °C 
followed by subsequent washing with 1× PBS. Next, 
cells were blocked for 30 min at RT with 1 % goat serum 
(DAKO; Copenhagen, Denmark) followed by incuba-
tion with a monoclonal mouse LC3 antibody (LC3-5F10, 
1:100; nanoTools; Teningen, Germany) which binds to 
the human LC3-I (18  kDa) and LC3-II (16  kDa) forms. 
Subsequently, cells were washed again three times with 
1× PBS before incubation with an Alexa Fluor-488 goat 
anti-mouse IgG (H + L) secondary antibody (Molecular 
Probes; Vienna, Austria) was performed for 30  min at 
RT under moisturized conditions. Thereafter, cells were 
washed again three times and were counterstained with 
Hoechst 33342 staining solution in 1× PBS (1  µg/ml) 
for 15  min at RT. After washing cells once in 1× PBS, 
fluorescence of LC3 positive cells was finally monitored 
on a Zeiss confocal laser scanning microscope using 
the LSM510 Meta software with an excitation/emis-
sion wavelength of 488/519  nm for green fluorescence. 
The mean fluorescent intensity of the measured green 
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fluorescence was calculated and presented in arbitrary 
units. SAHA treated cells were included as a positive 
control and untreated or TP53-637C>T-transfected cells 
as negative control. Representative measurements, where 
similar results were obtained in three independent exper-
iments, are shown.
Statistical analysis
All values represent means of at least three independent 
experiments ± standard deviation (SD) of at least tripli-
cate measurements. Statistical significance (p) was cal-
culated using Student’s t test. A p ≤ 0.05 was considered 
statistically significant. Statistically significant differences 
as compared to the untreated control if not stated other-
wise were indicated by asterisks (*).
Results
In a previous study, we compared the effectiveness of 
single SAHA versus combined SAHA and TRAIL treat-
ment in terms of apoptosis induction [20]. 3 µM SAHA 
and 100 ng/ml TRAIL were established as the final most 
effective concentration for all further experiments. In 
both tumor cell lines, induction of single SAHA and 
synergistic SAHA- and TRAIL-induced apoptosis was 
accompanied by upregulation of the intrinsic apoptotic 
pathway verified by reduction of mitochondrial mem-
brane potential, quantitative bivariate cytofluorometric 
analysis with Annexin V/propidium iodide, activation of 
effector caspases, and PARP cleavage. Nevertheless, in 
comparison, caspase-3/-7 activation was about two-fold 
higher in MES-SA cells than in ESS-1 cells which was 
consistent with the previously determined prevailing 
autophagy in ESS-1 cells. In order to detect any causes 
explaining the variable acitivation of the intrinsic/mito-
chondrial apoptotic pathway in ESS-1 and MES-SA cells, 
respectively, we analyzed the expression levels of the 
different cell cycle—and apoptosis-related key proteins 
p21WAF1, p53, and PUMA (p53 upregulated modula-
tor of apoptosis) a member of the Bcl-2 protein family, 
by immunoblotting. As demonstrated in Fig.  1a, b, we 
detected essentially no irregular expression levels of the 
cyclin-dependent kinase inhibitor p21WAF1. As expected, 
higher p21WAF1 levels were observed in ESS-1 cells that 
received the combined treatment or single SAHA treat-
ment whereas untreated or single TRAIL-administered 
cells exhibited only weakly expressed p21WAF1 protein 
in comparison. Surprisingly, however, expression of the 
tumor suppressor protein p53 was completely undetecta-
ble in ESS-1 cells when compared to the easily detectable 
and abundant expression in MES-SA cells. Furthermore, 
in relation to MES-SA cells lower PUMA levels were 
present in all treated ESS-1 samples within the range of 
the untreated control. This observation suggested that 
apoptosis resistance is caused by p53-deficiency via 
the p53-mediated pathway and associated with lacking 
PUMA upregulation in ESS-1 cells.
Identification of a nonsense mutation in the TP53 gene 
of ESS‑1 cells
In order to verify the results of p53 immunoblotting 
suggesting the presence of a genomic deletion or muta-
tion (Fig. 1), nuclear DNA was isolated from ESS-1 and 
MES-SA cells. However, when amplifying genomic DNA 
from different exonic regions of TP53, specific PCR frag-
ments were present upon agarose gel electrophoresis 
indicating the absence of a large genomic deletion in 
ESS-1 cells (data not shown). As a consequence, all TP53 
exons were PCR amplified from ESS-1 and MES-SA cells, 
subcloned, and the nucleotide sequence was analyzed 
for the presence of mutations. Thereby, in ESS-1 cell 
derived genomic DNA, a homozygous 637C>T transition 






































































Fig. 1 Expression analyses of key regulators of cell cycle and 
apoptosis in SAHA-treated uterine sarcoma cells. a Western blot 
analysis of ESS-1 and MES-SA cells treated for 8 h with 3 µM SAHA 
and/or 100 ng/ml TRAIL. Cell extracts were prepared, subjected to 
SDS-PAGE, and immunoblotted with antibodies against p21WAF1, p53, 
PUMA (23 kDa), and β-tubulin (as loading control). b Quantification 
of p21WAF1 and PUMA protein expression in relation to beta-tubulin 
expression
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in exon 6 of TP53 was revealed that was not present in 
MES-SA cells. This point mutation generates an early 
stop codon, resulting in a truncated p53 protein missing 
the C-terminal ~180 of 393 amino acids. At the protein 
level, the R213X non-sense mutation is located at the 
N-terminal region of the DNA binding domain (DBD) 
of p53 as depicted in Fig. 2. This finding implicated that 
apoptosis resistance or induction of autophagy is related 
to p53-deficiency due to the TP53-637C>T mutation in 
ESS-1 cells.
TP53 gene transfer restores SAHA‑induced apoptosis 
in ESS‑1 cells
Next, we wanted to determine whether SAHA-induced 
apoptosis depends on the expression of a functional p53 
protein (Figs. 3, 4). A full-length TP53 cDNA expression 
construct (TP53-WT) encoding the wildtype tumor sup-
pressor protein and a constructed 637C>T mutated TP53 
gene (TP53-637C>T) (Fig.  3a) were used to transiently 
transfect ESS-1 cells. This resulted in the expression of a 
detectable protein only in the case of the TP53-WT con-
struct (Fig. 3b). Surprisingly, following 3 µM SAHA treat-
ment, transfected cells underwent close to complete lysis 
24  h later (Fig.  3c). This finding led to the conclusion, 
that p53 expression restored SAHA-induced apoptosis 
in ESS-1 cells. For direct confirmation of this assump-
tion, we tested for upregulation of the pro-apoptotic pro-
teins PUMA, caspase-9 and PARP-1 by immunoblotting 
(Fig.  3d). Six hours after TP53-WT-transfected ESS-1 
cells were induced with SAHA, PUMA and caspase-9 
were found to be expressed at higher levels in compari-
son to untreated or TP53-637C>T-transfected control 
cells. 12 h after transfection, this difference in expression 
declined presumably due to fast-acting reactivated apop-
tosis eliminating most cells by this time point. Neverthe-
less, for both time points sufficient cleavage of PARP-1 
could be detected in cells transfected with TP53-WT, 
indicative for re-established apoptosis.
Fig. 2 Identification of a nonsense mutation detected in the TP53 gene of ESS-1 cells. a Depiction of the nucleotide sequence of exon 6 of TP53 
and the deduced encoded amino acid sequence of the p53 protein. Presented is the wildtype (WT) and the mutated sequence with a C>T transi-
tion in nucleotide position 637 of ESS-1 cells (ESS-1). The point mutation leads to the formation of a premature stop (TGA) codon at amino acid resi-
due 213. b Nucleotide sequence traces of MES-SA (left box) and ESS-1 cells (right box) demonstrating the wild-type or mutated sequence (red arrow) 
presented in the shaded box in a, respectively. c Schematic representation of the p53 protein with its domains (not drawn to scale) and indication 
of the N-(N) and C-terminal c end. The R213X non-sense mutation is located at the N-terminal end of the DNA binding domain (DBD) of the p53 
protein. As a consequence, a resulting truncated p53 protein would lack ~ 180 out of 393 amino acids at the C-terminal end
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Fig. 3 TP53 gene transfer restores apoptosis induction by SAHA in ESS-1 cells. a The expression vector pCMV6-XL5 containing the CMV promoter, 
either wild-type (TP53-WT; upper panel) or the constructed 637C>T mutated (TP53-637C>T; lower panel) human full-length cDNA for TP53, and 
the signal sequence for the human growth hormone signal (hGH polyA). b Detection of p53 expression by Western blot in ESS-1 cells transiently 
transfected with the TP53-WT or -637C>T expression vectors. MES-SA cells were used as a positive control. β-tubulin was used as loading control. c 
Transient transfection of ESS-1 cells with TP53-WT and TP53-637C>T expression constructs shown in a. Following 3 µM SAHA treatment, TP53-WT-
transfected cells underwent close to complete lysis 24 h after transfection (upper middle panel) while no obvious effects could be seen in SAHA-
treated (upper panel) or –untreated (lower panel) ESS-1 (left panel) and TP53-637C>T transfected (right panel) control cells. (Magnification: 20-fold) 
d Screening for p53-induced mitochondria-mediated apoptosis by Western blot analysis. Cell extracts of ESS-1 cells that were untreated (U) or 
transiently transfected with TP53-WT, or TP53-637C>T expression vectors and were treated or non-treated (CO; 6 h) with 3 µM SAHA were electro-
phoresed by SDS PAGE, blotted, and monitored after 6 or 12 h with antibodies against the cleaved pro-apoptotic protein PUMA (23 kDa), caspase-9 
(CASP-9; 35/37 kDa), and cleaved PARP-1 (89 kDa). β-tubulin was used as loading control
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Subsequently, we tested whether the restoration of p53 
also resulted in activation of apoptotic executioner cas-
pases, in combination with LDH measurements, to assess 
the amount of apoptosis and cell-mediated cytotoxic-
ity (Fig. 4a). Apoptosis detection of transfected cells was 
done by monitoring the activation of caspases-3 and -7, 
and comparing to those of TP53-637C>T-transferred or 
combined SAHA and TRAIL treated cells. The results 
demonstrate that upon addition of SAHA transient res-
toration of TP53 full-length cDNA evoked re-induced 
activation of caspases-3 and -7 12  h after transfection 
of ESS-1 cells. The observed level of caspase induction 
was comparable to that obtained by combined SAHA 
and TRAIL treatment (~450 to 500  % of the untreated 
control). In contrast, single SAHA, TRAIL-treated, or 
solely TP53-WT transfected cells reached only about 
Fig. 4 Apoptosis executioner caspase re-activation and LDH release in TP53-rescued ESS-1 cells. a Caspase-3 and -7 activation (Caspase-Glo 3/7 
Assay) of TP53-WT- or TP53-637C>T-transfected ESS-1 cells that were treated with 3 µM SAHA. Different individual caspase inhibitors (C3i, C8i, C9i, 
CFi) were additionally applied together with SAHA to TP53-WT reconstituted cells as controls. Untreated, SAHA-, (S; 3 µM) and/or TRAIL-treated (T; 
100 nM), and untreated TP53-WT-transfected cells served as further controls. b Measurements of LDH release by the CytoTox-ONE homogeneous 
membrane integrity assay of the samples analyzed in A for determination of the amount of cell cytotoxicity. Statistically significant differences 
compared to the SAHA-treated control were indicated in a and b
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200–300  % of untreated control levels. TP53-637C>T 
control-transfected cells exhibited levels comparable to 
the untreated control (~100  %). ESS-1 cells pretreated 
with caspase inhibitors (caspase-3, -9, or broad spectrum 
caspase family) exhibited no detectable activation of cas-
pases-3 and -7 with the exception of caspase-8 inhibitor 
that is not interfering with the p53-mediated apoptotic 
pathway. The caspase-3/-7 peak induced by TP53-WT-
transfected and SAHA-treated ESS-1 cells also coincided 
with a considerably increased LDH level in ESS-1 cells 
(~15  % of lysis control) (Fig.  4b). Nevertheless, at the 
investigated time-point, the levels of SAHA and TRAIL 
treated control cells were not yet reached (~28 % of lysis 
control), but were higher than that of cells supplied indi-
vidually with SAHA-, TRAIL-, TP53-WT- or SAHA and 
TP53-637C>T (~6 to 9  % of lysis control). Conversely, 
caspase-inhibitor supplemented cells only reached LDH 
amounts which were comparable to that of untreated 
control cells. However, again caspase-8 inhibitor showed 
no significant inhibitory effect. Overall, our results con-
firmed p53 dependant restoration of SAHA induced 
apoptosis in ESS-1 cells.
Downregulation of autophagy in TP53‑rescued and SAHA 
treated ESS‑1 cells
To investigate whether restoration of p53 wildtype 
expression exerts an effect upon SAHA-induced 
autophagy in ESS-1 cells, we used different methods to 
monitor any induced differences in this cellular process 
(Figs. 5, 6). First, a specific monoclonal antibody against 
the autophagic marker LC3 was used for fluorescence 
staining (Fig.  5a). 12  h after the initiation of treatment, 
only basal LC3 specific staining (mean fluorescence 
intensity) could be detected in p53 reconstituted ESS-1 
cells which received SAHA treatment in comparison to 
only SAHA-treated cells (~0.2 vs. ~3.9 arbitrary units) or 
SAHA and TP53-637C>T treated control cells (~0.2 vs. 
~2.3 arbitrary units). Nevertheless, even in the absence 
of SAHA-induced autophagy, untreated, as well as TP53-
WT treated control cells exhibited about fivefold higher 
levels of LC3 staining compared to TP53-transfected 
cells (~0.2 vs. ~1 arbitrary units). Also in SAHA- and 
TRAIL-induced control cells, in which apoptotic cell 
death is prevailing [20], LC3 staining still reached a level 
of ~1 arbitrary units. For mTOR immunoblotting analy-
sis, TP53-WT transfected cells were investigated after 
supplying them with 3 µM SAHA for 6 and 12 h (Fig. 5b). 
Consistent with basal induction of autophagy for both 
timepoints, bands comparable to the untreated control 
could be detected for the serine/threonin protein kinase 
mTOR and phosphorylated mTOR (p-mTOR); in con-
trast, rapamycin-treated or TP53-637CT-transfected 
control cells that were supplemented with SAHA showed 
decreased mTOR or p-mTOR signals indicative for 
induction of autophagy.
Next, we additionally employed MDC and PI stain-
ing to quantify and depict TP53 transfected ESS-1 cells 
regarding autophagosome formation and cytotoxicity 
(Fig.  6a, b). Upon SAHA treatment, TP53-WT-rescued 
cells displayed only marginal mean fluorescence intensity 
staining for MDC in comparison to untreated or TP53-
637C>T-transfected control cells (~0.5 vs 4 arbitrary 
units); single SAHA or rapamycin-induced positive ESS-1 
control cells, however, reached ~16 or 30-fold higher lev-
els of MDC staining, respectively. Surprisingly, pretreat-
ment of TP53-WT-transfected ESS-1 cells with the broad 
spectrum caspase family inhibitor suppressing caspase-
dependent apoptosis also led to considerable upregula-
tion of autophagosome formation (~11 arbitrary units). 
TP53-WT transfection with or without caspase-inhibitor 
addition provoked the highest observed cytotoxicity as 
indicated by PI staining which was ~fourfold higher than 
in all other control cells upon 12 h of treatment. Repre-
sentative confocal images of the cells used for MDC as 
well as PI fluorescence measurements in Fig. 6a are pre-
sented in Fig.  6b. Taken together, we showed that p53-
restored cells displayed diminished autophagic induction.
RNAi silencing of p53 expression induces autophagy 
in SAHA‑treated MES‑SA cells
In contrast to ESS-1 cells lacking p53 expression, we 
wanted to test whether downregulation of p53 expres-
sion in p53-proficient cells will induce autophagy. There-
fore, we employed RNA interference in MES-SA cells to 
silence its p53 expression (Fig.  7). Besides p53, mTOR 
and p-mTOR expression were examined by immunob-
lotting analysis. Transient transfection of MES-SA cells 
with p53 si-RNA demonstrated partially reduced p53 
expression which was not present in untreated or con-
trol si-RNA transfected cells. Diminished p53 expres-
sion furthermore correlated with reduced expression of 
both investigated mTOR proteins in SAHA-treated MES-
SA cells, comparable to rapamycin-treated control cells 
and thus indicated enhanced induction of autophagy. 
Untreated, SAHA-supplemented, or control si-RNA 
transfected cells lacked or showed only insignificantly 
decreased mTOR and p-mTOR signals, however. There-
fore, this experiment suggested that diminished p53 
expression could also lead to increased autophagic induc-
tion in MES-SA cells undergoing SAHA treatment.
Monitoring of TP53‑rescued tumor cell lines for apoptosis 
and autophagy induction
Next, we wanted to generally validate a role for the 
tumor suppressor protein p53 in switching between 
SAHA-mediated apoptosis and autophagy due to its 
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functional status or cytoplasmic presence in the cell. 
Therefore, upon TP53 reconstitution and administra-
tion of 3 µM SAHA, several TP53 mutant and SAHA-
responsive cell lines, which have been previously 
reported to undergo autophagy, were screened for their 
mode of cell death [27–30]. HeLa cells, that undergo 
SAHA induced apoptosis and possess a wildtype p53 
protein have been included as a control [31]. As dem-
onstrated in Fig.  8a, with the exception of HeLa con-
trol cells, the level of autophagy was downregulated in 
all investigated p53-deficient tumor cell lines (PANC-
1, Jurkat, HL-60, U937) after 24  h indicated by less 
Fig. 5 Downregulation of autophagy in TP53-rescued and SAHA-treated ESS-1 cells. a Fluorescence staining of TP53-WT resubstituted, TP53-
637C>T control-transfected, or non-transfected ESS-1 cells that were treated with 3 µM SAHA with a monoclonal antibody against the autophagy-
specific marker LC3. Graphs depict the mean fluorescence intensity of LC3 specific staining, 12 h after the initiation of treatment. Untreated, SAHA 
(3 µM)-, SAHA and TRAIL-treated (100 nM), as well as untreated TP53-WT-transfected cells were measured as controls. b For immunoblotting analysis 
with antibodies against mTOR (289 kDa) and phospho-mTOR (p-mTOR), TP53-WT- or TP53-637C>T control-transfected ESS-1 cells were analyzed 
6 and 12 h after treatment with or without SAHA. Untreated or rapamycin-supplied (2 µM) cells served as controls. β-tubulin was used as loading 
control
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detectable MDC staining; mean fluorescence levels 
were found to range from ~31 to ~65 % lower in com-
parison to non-transfected but also SAHA-treated 
cells. In line with this finding, also the amount of dead 
cells was found to be significantly reduced for ~53 to 
85  % for all TP53-WT transfected cell lines, when 
compared to control cells, as indicated by PI stain-
ing. Conversely, when apoptosis was monitored at this 
time point, the tumor cell panel exhibited ~76 to 157 % 
higher levels of caspase-3/-7 activation (Fig.  8b). Fur-
thermore, equal (HeLa cells) or slightly higher LDH 
levels ranging from 11 to 97  % were detected when 
TP53-WT was additionally transfected in comparison 
to only SAHA-treated tumor cells after 24  h (Fig.  8c). 
Conclusively, these analyses let us presume a general 
important role for p53 as a mediator in SAHA-driven 
apoptosis and autophagy.
Discussion
In this study, we searched for the cause of varying cel-
lular responses elicited by two human uterine sarcoma 
cell lines upon treating them with the HDACi SAHA. 
By screening several important pro-apoptotic key mol-
ecules, we found that expression of the tumor suppres-
sor protein p53 was completely undetectable in ESS-1 
cells when compared to the easily detectable and abun-
dant expression in MES-SA cells. Furthermore, only 
basal PUMA levels were present in relation to MES-SA 
Fig. 6 Downregulation of autophagy in TP53-rescued and SAHA-treated ESS-1 cells demonstrated by MDC/PI staining. a MDC (green) and PI stain-
ing (red) was performed of TP53-WT, TP53-637C>T, or non-transfected ESS-1 cells treated with 3 µM SAHA to quantify autophagosome formation 
and cytotoxicity, respectively. Untreated, SAHA, SAHA and TRAIL-treated, as well as TP53-WT-transfected cells were included as controls. Rapamycin-
supplied cells were included as a reference for induction of autophagy. TP53-WT-rescued cells pretreated with 10 µM caspase family inhibitor (CFi) 
served as a control to monitor the influence of caspase-dependent apoptosis. b Representative confocal images used for quantitative autophagic 
and cytotoxicity measurements in a. At least three different images resulting from three independent experiments were used for analysing MDC 
(upper panel; green fluorescence) and PI (lower panel; red fluorescence) staining. The scale bar indicates 50 µM (Magnification: 40-fold)
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cells. Irrespective of absent p53 expression, the promis-
ing anti-cancer compound SAHA increased expression 
of the cell cycle kinase inhibitor p21WAF1 which down-
regulates tumor cell proliferation via cell cycle arrest in 
the G1/S phase. This observation confirms a previous 
study which reported, in contrast to normally tightly 
p53-controlled expression, the possibility of p53-inde-
pendent activation of the p21WAF1 promoter by direct 
SAHA-mediated activation of SP1 sites [32]. Overall, 
this finding was in consistency with prevailing induc-
tion of autophagic cell death in ESS-1 cells [10] and 
the predominant apoptotic response in MES-SA cells 
provoked by SAHA as previously elaborated [20, 21]. 
Therefore, we searched for the molecular mechanism 
in which the absence of p53 expression originated. We 
detected a homozygous 637C>T transition in exon 6 
of the TP53 gene in the ESS-1 cell line which results in 
the formation of a premature stop codon. Since codon 
213 consists of a CpG dinucleotide, which is a target for 
cytosine methylation, the nonsense mutation at codon 
213 could have occurred in vitro in this cell line as the 
result of endogenous deamination of 5-methylcytosine 
to thymine. Upon database screening, we were also able 
to confirm this mutation by an entry in the COSMIC 
(catalogue of somatic mutations in cancer) database for 
human immortal cancer cell lines (http://www.cancer.
sanger.ac.uk/cancergenome/projects/cell_lines/). More-
over, this mutation has been verified and annotated 
for endometrial carcinoma [33]. The R213X non-sense 
mutation, which is not present in MES-SA cells, is 
located at the N-terminus of the DNA binding domain 
(DBD) of p53 and leads to a truncated protein that is 
missing the last ~180 of 393 amino acids. Although we 
used a monoclonal human-specific p53 antibody (clone 
DO-7) that recognizes an epitope between amino acids 
1–45 of wildtype as well as mutant forms of p53, we 
were not able to detect the presumptive truncated p53 
protein in our experiments. In support of our find-
ing, also ovarian cancer patients possessing the R213X 
mutation exhibited null type mutations that could not 
be detected by immunohistochemical staining for 
unknown reasons [34].
The apoptosis-inducing functions of p53 are exerted in 
two ways: one is through the transcriptional activation of 
pro-apoptotic proteins such as Puma, Noxa and Bax, the 
other is via direct physical and functional interaction with 
members of the Bcl-2 protein family that cause mito-
chondrial membrane permeabilization. The identified 
homozygous p53 mutation thus clearly explains apop-
tosis resistance in ESS-1 cells as in the case of complete 
p53-deficiency, no physical interactions or transcrip-
tional activities can take place at all. Alternatively, in case 
of undetectable p53 protein, it was previously reported 
that the R213X mutation disrupted the efficiency of p53 
transactivation by its inability to bind consensus binding 
sequences of p53 in the regulatory region of the p21WAF 
gene [35]. In addition, this mutation was also found to 
be a dominant negative p53 variant which suppresses 
the endogenous wild-type function [36]. Beyond that, 
we hypothesized that p53 could be the missing link lead-
ing to either SAHA-induced autophagy in the absence of 
the p53 protein or preferential SAHA-stimulated apop-
tosis when a functional wild type molecule is present in 
the cell. In support of this, in addition to its many other 
tumor suppressing activities, p53 has been identified as 
a major regulator of autophagy in recent time [37–40]. 
Autophagy induced by p53 may facilitate p53’s cell cycle 
arrest activities, such that autophagy mediates the selec-
tive degradation of damaged molecules and organelles in 
order to provide an energy source for the damage repair 
process and promote ‘cell healing’. Alternatively, when 
the extent of damage is beyond repair, autophagy may 
act to synergize with accelerated cell death in response 
to p53 activation. While the autophagy-promoting activ-
ity of p53 requires the presence of p53 in the nucleus, 
associated with transcriptional activity, the autophagy-
suppressing function of p53 was found to completely 
depend on its cytoplasmic presence without transcrip-
tional dependence. Both, autophagy-promoting as well 
as -inhibiting activities of p53, engage the mTOR signal-
ing pathway which in response to genotoxic or metabolic 
stress cross-talks with p53 in a coordinated fashion [41]; 
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Fig. 7 Si-RNA mediated knockdown of p53 expression in MES-SA 
cells. Immunoblotting analysis was used to monitor the amount of 
silencing of p53 expression, and the resulting mTOR (289 kDa) and 
p-mTOR expression indicating autophagic induction 36 h after tran-
siently transfecting MES-SA cells with si-RNA for p53 (50 and 100 nM) 
or non-targeted control si-RNA (100 nM). SAHA-treatment (3 µM) 
was started 12 h before analysis. Untreated, only SAHA-treated, or 
rapamycin-supplied cells served as additional controls. β-tubulin was 
used as loading control
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Fig. 8 Monitoring of TP53-rescued tumor cell lines for apoptosis and autophagy induction. a A TP53-proficient (HeLa) and several TP53-mutant and 
SAHA-responsive tumor cell lines (PANC-1, Jurkat, HL-60, and U937 cells) were transfected either with TP53-WT or with TP53-637C>T, respectively. 
After 24 h of 3 µM SAHA treatment, MDC and PI fluorescence was quantified in order to monitor resulting changes in autophagy and cytotoxicity. 
b To assess apoptotic activity in TP53-WT reconstituted tumor cell lines as described in a, caspase-3 and -7 activation (Caspase-Glo 3/7 Assay) was 
measured upon 3 µM SAHA treatment for 24 h and compared to untreated, or only SAHA-treated cells. c Additionally, the amount of LDH release 
was determined from cells used for the experiment in b. Statistically significant differences compared to the SAHA-treated control are indicated in 
a–c
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thus, both signaling machineries regulate cell growth, 
proliferation, and death together. This mechanism of 
p53-induced autophagy involves activation of 5′ AMP-
activated protein kinase (AMPK) as well as the tuberus 
sclerosis complex kinases, TSC1 and TSC2, which finally 
inhibit mTOR kinase. Indeed, after rescue of ESS-1 cells 
with wildtype TP53 we found in our experiments that 
the balance between predominant autophagy and apop-
tosis was directed towards prevailing apoptosis and basic 
autophagy; this observation was supported by upregu-
lation of PUMA, as well as by activation of the apopto-
sis initiator and executioner caspases 9,-3 and -7, and 
finally by PARP-1 cleavage. In contrast, downregulation 
of autophagy was supported by mTOR/phosphor-mTor 
immunoblotting, staining with the autophagic marker 
LC3 as well as specific autophagosome staining with 
MDC [25]. These results could identify p53 as a molecu-
lar switch that directly mediates the response of SAHA 
by either executing pro-apoptotic signalling; mecha-
nistically this could possibly be accomplished by direct 
acetylation of the protein or by promoting the formation 
of autophagy upon the absence of p53 in the tumor cell. 
Accordingly, a study demonstrated that complexes con-
stituted by acetylated p53 as well as acetylated histones 
and coactivators were held responsible for HDACi-
induced apoptosis in HepG2 cells [42]. If proven true, 
these findings furthermore might have immediate impli-
cations in the choice of cancer therapeutics and make our 
experimental system interesting for further molecular 
analysis regarding SAHA-provoked cell death regulation.
Conclusions
Taken together, we conclude that in ESS-1 and MES-SA 
cells and at least in a subset of tumor cell lines in gen-
eral, p53 could be essential in mediating SAHA–induced 
apoptosis, while absence or degradation of p53 in the 
cytoplasmic compartment could lead to activation of a 
SAHA-mediated autophagic pathway. Overall, our data 
provide encouraging evidence for an inhibitory role of 
a p53-driven autophagic response elicited by the SAHA 
pathway in tumor cells and the requirement of p53 for 
undergoing SAHA-induced apoptotic cell death. Thus, 
mutant p53 re-activation using a well-tolerated small 
molecule inhibitor or inhibitors of MDM2-mediated pro-
teasomal degradation might help to restore p53-depend-
ent apoptosis and tumor suppression. As nonsense TP53 
mutations of which the 637C>T mutant is found most 
often are even more common in human tumors than 
TP53 missense mutations (listed in the UMD TP53 
muatation database; http://p53.free.fr), their restora-
tion by drugs will be of significance but require different 
approaches. Currently, aminoglycosides (e.g. gentamicin 
and G418), can achieve read-through of the 637C>T 
transition leading to expression of full-length p53, how-
ever due to their toxicity further screening for less toxic 
compounds is necessary [43]. The resulting molecular 
shift from autophagy towards apoptosis could then help 
in the efficient removal of tumor cells in affected patients 
[44]. In addition, in a subset of tumor cells where inhi-
bition of autophagy causes non-apoptotic cell death, the 
therapeutic potential of autophagy targeting in combina-
tion with SAHA therapy could be employed [45].
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